Clinical Scorecard: Pneumococcal Haemolytic Uraemic Syndrome Incidence After PCV15 Introduction in Sweden
At a Glance
Category
Detail
Condition
Pneumococcal haemolytic uraemic syndrome (pHUS), an uncommon serious complication of invasive pneumococcal disease in children
Key Mechanisms
Pneumococcal serotypes are defined by capsular polysaccharides; vaccine serotype coverage may affect circulation of strains associated with pHUS.
Target Population
Children in Sweden, with pHUS incidence assessed in relation to changes in the national pneumococcal immunisation programme
Care Setting
Swedish national paediatric surveillance and immunisation programme; the study reports population-level incidence rather than individual clinical care.
Key Highlights
Sweden recorded no pHUS cases in 2025, corresponding to an incidence of 0 per 100,000 children.
PCV10 was replaced by PCV15 in Sweden in 2023; PCV15 includes serotypes 3 and 19A, neither of which is included in PCV10.
A previous Swedish investigation documented an approximately 10-fold rise in pHUS incidence after PCV13 was replaced by PCV10 in 2019.
Paediatric invasive pneumococcal disease declined after PCV15 introduction; adults were not directly exposed to the childhood vaccination programme and did not show a similar decline.
The ecological findings cannot establish causality; the authors note possible natural fluctuations, secular epidemiological changes, and stochastic effects.
Guideline-Based Recommendations
Diagnosis
Management
The authors state that their findings underscore the importance of preserving broad pneumococcal serotype coverage through vaccination.
Monitoring & Follow-up
The authors state that ongoing national surveillance is needed to determine whether the absence of pHUS cases in 2025 reflects a sustained trend.
Risks
The rarity of pHUS means incidence may be affected by stochastic variation.
The ecological study design cannot demonstrate that PCV15 caused the observed decline.
Patient & Prescribing Data
Children in Sweden; the article reports national surveillance findings and does not provide individual patient prescribing data.
The article describes changes in vaccine programme coverage: PCV13 was replaced by PCV10 in 2019, and PCV10 was replaced by PCV15 in 2023. It does not report individual treatment regimens.
Clinical Best Practices
The authors state that ongoing national surveillance will be essential to determine whether the absence of cases in 2025 reflects a sustained trend.
Interpret the temporal association between vaccine replacement and pHUS incidence cautiously because the ecological study cannot establish causality.
The authors note that changing pneumococcal epidemiology is relevant when considering vaccine serotype coverage.
